Welcome to our dedicated page for ESTABLISHMENT LABS HOLDINGS SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Establishment Labs Holdings Inc. filings document regulatory disclosures for a British Virgin Islands medical technology issuer listed on Nasdaq. Its Form 8-K reports cover operating results and financial condition, preliminary financial information, Regulation FD presentation materials, credit-agreement amendments, senior secured term-loan obligations, and other material definitive agreements.
The company’s proxy materials disclose board matters, executive compensation, equity awards, shareholder voting items, and governance practices. Together, the filings describe the Motiva-focused breast aesthetics and reconstruction business, capital structure, debt arrangements, forward-looking-statement disclosures, and recurring corporate reporting obligations.
Establishment Labs Holdings (ESTA) reported an insider transaction on a Form 4 involving multiple reporting persons affiliated with JW Asset Management. On 11/06/2025, the group sold 7,591 Common Shares at a price of $65 per share, coded “S” for sale. Following the transaction, 3,075,194 shares were reported as beneficially owned in aggregate with indirect ownership noted.
Footnotes state the sale comprised 5,662 shares by JW Partners, LP and 1,929 shares by JW Opportunities Fund, LLC. The filing lists JW Asset Management, LLC, JW Partners, LP, JW Opportunities Fund, LLC, JW GP, LLC, and Jason G. Wild as reporting persons, with customary beneficial ownership disclaimers. The form indicates it was filed by more than one reporting person.
Establishment Labs (ESTA) reported Q3 2025 results. Revenue reached $53.8 million, up from $40.2 million a year ago, with gross profit of $37.7 million. Operating loss narrowed to $4.0 million and net loss was $11.1 million, or $0.38 per share.
North America contributed $11.9 million in Q3 revenue versus $0.3 million in the prior year period. For the first nine months, revenue was $146.5 million and net loss was $48.4 million.
Cash and cash equivalents were $70.6 million at quarter-end. Year-to-date net cash used in operating activities was $50.7 million. Note payable, net, increased to $246.5 million from $219.6 million at year-end 2024, and shareholders’ equity declined to $16.4 million from $53.1 million. The company had 29,057,868 common shares outstanding as of November 6, 2025.
Establishment Labs Holdings Inc. (ESTA) furnished an update on its business by announcing financial results for the three and nine months ended September 30, 2025. The company made these results available through a press release attached as Exhibit 99.1. The disclosure under Item 2.02 is furnished and not filed under the Exchange Act.
Establishment Labs Holdings Inc. entered into a fourth amendment to its credit agreement with Oaktree Fund Administration. The amendment makes the Tranche D term loans available as of the amendment’s effective date, removing the need to first achieve the revenue milestone originally required. It also raises the minimum liquidity the company and its guarantor subsidiaries must maintain from $25,000,000 to $30,000,000, effective September 28, 2025.
On the same day, the company fully drew the available Tranche D term loans, resulting in a new borrowing of $25,000,000 under the credit agreement. The amendment itself is filed as an exhibit to provide full details of the revised terms.
Edward J. Schutter, a director of Establishment Labs Holdings Inc. (ESTA), received 457 common shares as payment in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy. The shares were issued under the Issuer’s 2018 Equity Incentive Plan and were valued based on the closing market price used to determine the share equivalent. After this issuance the reporting person beneficially owns 138,015 shares, held directly.
Establishment Labs Holdings Inc. (ESTA) director Ann Custin acquired 503 common shares on 09/30/2025 at a price of $40.99 per share. The shares were issued under the company’s 2018 Equity Incentive Plan and were elected in lieu of a quarterly cash retainer under the issuer’s Outside Director Compensation Policy; the number of shares was determined using the closing price on the last trading day of the quarter. Following the transaction, the reporting person beneficially owned 21,087 shares. The Form 4 was signed by the company’s CFO by power of attorney on 10/01/2025.
Establishment Labs Holdings director Nicholas Sheridan reported acquiring 609 common shares on 09/30/2025 at a price of $40.99 per share. These shares were issued under the company’s 2018 Equity Incentive Plan and represent shares elected to be received in lieu of a quarterly cash retainer under the issuer’s Outside Director Compensation Policy.
After the transaction the reporting person directly beneficially owned 1,076,532 shares. An additional 19,090 shares are noted as indirectly beneficially owned via the reporting person’s spouse. The Form 4 discloses this routine director compensation election and does not show derivative transactions.
Reporting person: Leslie Gillin, a director of Establishment Labs Holdings Inc. (ESTA), acquired common shares as director compensation.
Transaction details: On 09/30/2025 the reporting person received 411 common shares issued under the company's 2018 Equity Incentive Plan at an effective price of $40.99 per share, representing shares elected in lieu of a quarterly cash retainer. Following the issuance the reporting person beneficially owned 15,516 common shares directly. The transaction was reported on Form 4 and signed by power of attorney on 10/01/2025.
JW Asset Management, JW Partners, JW Opportunities Fund, JW GP and Jason G. Wild reported writing and selling 940 call options on Establishment Labs Holdings Inc. (ESTA) on 08/22/2025. Each option contract covers 100 shares, so the transaction represents rights on 94,000 shares with a $42.50 strike and an option price of $2.1802 per share. The reported position shows 94,000 underlying shares associated with the calls and is held indirectly through affiliated entities. The filing identifies the advisor and affiliated entities as joint reporting persons and explains their relationships.
Establishment Labs Holdings director Nicholas Sheridan Lewin reported an indirect open-market purchase of 2,600 common shares of ESTA on August 14, 2025 at $37.85 per share. The acquired shares are held by his spouse, with Lewin reporting indirect beneficial ownership of 19,090 shares and direct ownership of 1,075,923 shares.